QurAlis scores $42m Series A
Cambridge, Massachusetts-based QurAlis Corporation, a developer of precision therapeutics for amyotrophic lateral sclerosis and other neurologic diseases, has secured $42 million in Series A financing.
Cambridge, Massachusetts-based QurAlis Corporation, a developer of precision therapeutics for amyotrophic lateral sclerosis and other neurologic diseases, has secured $42 million in Series A financing.
Copyright PEI Media
Not for publication, email or dissemination